Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

NCT06001151 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Cadonilimab
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

Qian Chu

Collaborators

[object Object]